AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity

Abstract

Although the advent of tyrosine kinase inhibitors (TKIs) has dramatically improved the survival of patients with chronic myeloid leukaemia (CML), acquired drug resistance and TKI-insensitive leukaemic stem cells (LSCs) remain major obstacles to a CML cure. In recent years, the reprogramming of mitochondrial metabolism has emerged as a hallmark of cancers, including CML, and in turn may be exploited for therapeutic purposes. Here, we investigated the effects of several drugs on the mitochondrial function of the CML cell line K562 and found that 5-aminoimidazole-4-carboxamide ribotide (AICAR) and decitabine could effectively increase the ATP content and mitochondrial biogenesis. In addition, these two drugs induced cell cycle arrest and a decrease in colony-forming capacity and promoted K562 cell differentiation. Moreover, we demonstrated that treatment with AICAR or decitabine enhanced the sensitivity of K562 cells to imatinib, as evidenced by a combination treatment assay. Altogether, our findings indicate that TKIs combined with mitochondrial regulation may provide a therapeutic strategy for the treatment of CML.

Keywords

chronic myeloid leukaemia / mitochondrial activity / 5-aminoimidazole-4-carboxamide ribotide (AICAR) / decitabine

References

[1] MeloJV, BarnesDJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Rev, Cancer, 2007, 7(6): 441-453

[2] SasakiK, StromSS, O’BrienS, et al.. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol, 2015, 2(5): e186-e193

[3] BowerH, BjorkholmM, DickmanPW, et al.. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol, 2016, 34(24): 2851-2857

[4] SoveriniS, ManciniM, BavaroL, et al.. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer, 2018, 17(1): 49

[5] ChuS, McdonaldT, LinA, et al.. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood, 2011, 118(20): 5565-5572

[6] HolyoakeTL, VetrieD. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood, 2017, 129(12): 1595-1606

[7] JainP, KantarjianHM, GhorabA, et al.. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123(22): 4391-4402

[8] NunnariJ, SuomalainenA. Mitochondria: in sickness and in health. Cell, 2012, 148(6): 1145-1159

[9] TennantDA, DuranRV, GottliebE. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer, 2010, 10(4): 267-277

[10] WarburgO. On the origin of cancer cells. Science, 1956, 123(3191): 309-314

[11] FantinVR, St-PierreJ, LederP. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9(6): 425-434

[12] VanderH M, CantleyLC, ThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324(5930): 1029-1033

[13] PavlovaNN, ThompsonCB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab, 2016, 23(1): 27-47

[14] KuntzEM, BaqueroP, MichieAM, et al.. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med, 2017, 23(10): 1234-1240

[15] GottschalkS, AndersonN, HainzC, et al.. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res, 2004, 10(19): 6661-6668

[16] Horibata S, Vo TV, Subramanian V, et al. Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells. J Vis Exp, 2015(99):e52727

[17] TsiftsoglouAS, PappasIS, VizirianakisIS. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther, 2003, 100(3): 257-290

[18] AgathocleousM, HarrisWA. Metabolism in physiological cell proliferation and differentiation. Trends Cell Biol, 2013, 23(10): 484-492

[19] HolyoakeTL, HelgasonGV. Do we need more drugs for chronic myeloid leukemia?. Immunol Rev, 2015, 263(1): 106-123

[20] VyasS, ZaganjorE, HaigisMC. Mitochondria and Cancer. Cell, 2016, 166(3): 555-566

[21] BogackaI, XieH, BrayGA, et al.. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes, 2005, 54(5): 1392-1399

[22] GhoshS, PatelN, RahnD, et al.. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol, 2007, 71(6): 1695-1702

[23] KukidomeD, NishikawaT, SonodaK, et al.. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes, 2006, 55(1): 120-127

[24] NohYH, KimK, ShimMS, et al.. Inhibition of oxidative stress by coenzyme Q10 increases mitochondrial mass and improves bioenergetic function in optic nerve head astrocytes. Cell Death Dis, 2013, 4: e820

[25] CortonJM, GillespieJG, HawleySA, et al.. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur J Biochem, 1995, 229(2): 558-565

[26] CantóC, Gerhart-HinesZ, FeigeJN, et al.. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature, 2009, 458(7241): 1056-1060

[27] WelchJS, PettiAA, MillerCA, et al.. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med, 2016, 375(21): 2023-2036

[28] SantiniV, KantarjianHM, IssaJP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med, 2001, 134(7): 573-586

[29] DuL, YangF, FangH, et al.. AICAr suppresses cell proliferation by inducing NTP and dNTP pool imbalances in acute lymphoblastic leukemia cells. FASEB J, 2019, 33(3): 4525-4537

[30] ShinDY, Sung KangH, KimG, et al.. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Biomed Pharmacother, 2013, 67(4): 305-311